Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GRI Bio, Inc. (NASDAQ: GRI) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-generated highlights to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on NKT cell modulators for inflammatory, fibrotic and autoimmune diseases, GRI Bio uses its filings to report on clinical progress, financing transactions, governance matters and risk factors relevant to GRI stock.
Among the most informative documents are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, pipeline programs such as GRI-0621 for idiopathic pulmonary fibrosis and type 2 dNKT agonists for systemic lupus erythematosus, and its status as a smaller reporting and emerging growth company. These filings also summarize key agreements, intellectual property and the broader risk profile associated with clinical-stage drug development.
GRI Bio’s Form 8-K current reports highlight material events, including:
- Topline and interim data from the Phase 2a GRI-0621-IPF-02 trial in IPF, covering safety, biomarker changes, alveolar basement membrane repair markers and forced vital capacity (FVC) analyses.
- Details of public offerings of common stock, pre-funded warrants and Series F warrants, including purchase agreements, warrant terms and expected use of proceeds.
- Corporate actions such as amendments to the 2018 Equity Incentive Plan and annual meeting voting results.
On this page, users can also review registration statements on Form S-1 and amendments, which outline securities offerings and include extensive exhibit lists covering warrants, purchase agreements and other contracts. Proxy statements (DEF 14A) provide insight into board structure, compensation plans and shareholder proposals.
Stock Titan’s interface surfaces AI-powered summaries of lengthy filings to explain key points in plain language, such as how a financing may affect capital structure or how reported IPF trial data relate to GRI-0621’s development. Real-time updates from EDGAR ensure new 10-K, 10-Q, 8-K, S-1 and related forms appear promptly, while dedicated sections for insider and beneficial ownership information can be explored through the company’s broader filing history.
Use this GRI filings hub to quickly locate and interpret the regulatory documents that shape the investment narrative around GRI Bio’s NKT cell–focused pipeline and its Nasdaq-listed common stock.
GRI Bio is offering 5,450,774 shares of common stock issuable upon exercise of its Series E-1, Series E-2, Series E-3, pre-funded and placement agent warrants under a prospectus supplement, following completion of a reasonable best efforts offering of 202,000 common shares and the related warrants.
The company also reports topline data from its Phase 2a GRI-0621-IPF-02 trial in idiopathic pulmonary fibrosis, where oral GRI-0621 met the primary endpoint of safety and tolerability over 12 weeks, showed placebo-adjusted improvements in forced vital capacity and favorable collagen biomarker shifts suggestive of anti-fibrotic activity, and produced no treatment-related serious adverse events in the 35-subject study.
GRI Bio, Inc. reported topline Phase 2a data for its oral drug candidate GRI-0621 in idiopathic pulmonary fibrosis, showing the trial met its primary endpoint of safety and tolerability over a 12-week treatment period. The company reports GRI-0621 was well tolerated with no treatment-related serious adverse events and adverse events mainly limited to grade 2 and grade 3 issues such as dry skin, dry lips, and musculoskeletal pain.
Placebo-adjusted changes in lung function, measured by Forced Vital Capacity, improved in patients receiving GRI-0621 alone and in combination with standard of care, and a higher share of treated patients experienced FVC increases compared with placebo. Serum biomarkers of multiple collagen types suggested an anti-fibrotic effect and potential activation of alveolar basement membrane repair, which are important for lung tissue recovery. The randomized, double-blind trial enrolled 35 IPF patients, most on background pirfenidone or nintedanib, and secondary and exploratory biomarker and pharmacodynamic analyses are ongoing.
GRI Bio filed a prospectus supplement registering 5,450,774 shares of common stock issuable upon exercise of previously issued Series E-1, E-2, E-3, pre-funded, and placement agent warrants, offered on a continuous basis under Rule 415. The related “reasonable best efforts” offering—covering 202,000 common shares, 1,186,888 pre-funded warrants, 1,388,888 Series E-1 warrants, 1,388,888 Series E-2 warrants, 1,388,888 Series E-3 warrants, and 97,222 placement agent warrants—was completed on April 2, 2025.
Alongside, the company reported quarterly results: cash and cash equivalents were $4.055 million as of September 30, 2025. Net loss was $3.359 million for the quarter and $9.297 million year-to-date, driven by research and development of GRI-0621 and higher general and administrative costs. The company noted substantial doubt about its ability to continue as a going concern based on current resources.
Shares outstanding were 3,268,727 as of November 13, 2025. GRI-0621’s Phase 2a biomarker study in idiopathic pulmonary fibrosis completed enrollment in July 2025, with topline results expected by the end of November 2025.
GRI Bio, Inc. filed its Q3 2025 10-Q, reporting a quarterly net loss of $3,359 on operating expenses of $3,365 (both in thousands). Cash and cash equivalents were $4,055, with management stating resources are sufficient into the first quarter of 2026 and disclosing substantial doubt about the ability to continue as a going concern without additional financing.
Year to date, operating cash use was $7,215, partially offset by financing inflows, including $5,000 from April 2025 offering proceeds and $2,560 through the ATM program (gross, in thousands). The company increased additional paid-in capital to $51,030 and ended the quarter with stockholders’ equity of $1,993 (in thousands). As of November 13, 2025, 3,268,727 common shares were outstanding.
GRI continues a Phase 2a biomarker study of GRI-0621 in IPF, with topline results expected by the end of November 2025. The pipeline also includes GRI-0803, with further progress dependent on funding.
GRI Bio, Inc. (GRI) reported an insider derivative transaction by Chief Financial Officer Leanne Kelly. The filing shows an award of a stock option covering 43,222 shares with an exercise price of $1.93. The option is exercisable immediately and expires in 2035. Of the options, 29,923 vested in full at grant and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary. The reporting person holds these options directly following the transaction.
GRI Bio, Inc. reporting person David Leslie Szekeres received a stock option award totaling 39,897 shares exercisable at $1.93. The options were granted and reported with a transaction date of 09/18/2025, become exercisable immediately for 29,293 shares and for the remaining 9,974 shares vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of grant. The options expire on 09/18/2035 and are reported as direct beneficial ownership, leaving 39,897 shares underlying the option beneficially owned after the transaction.
GRI Bio, Inc. (GRI) director David Charles Baker was granted a stock option on 09/18/2025 to buy 23,605 shares of common stock at a $1.93 exercise price. The option becomes exercisable on 09/18/2025 and expires on 09/18/2035. Of the total, 17,621 options vested immediately on the grant date and 5,984 options will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The Form 4 was filed by a single reporting person and signed via attorney-in-fact on 09/22/2025.
GRI Bio insider option grant: Director Camilla V. Simpson was granted a stock option on 09/18/2025 to buy 23,605 shares of GRI Bio common stock at a $1.93 exercise price. Of the option, 17,621 shares vested immediately on the grant date and 5,984 shares will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The option expires on 09/18/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/22/2025.
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio director Roelof Rongen reported a stock option grant that became partially vested on 09/18/2025. The filing shows options to purchase 23,605 shares of common stock at an exercise price of $1.93 per share, exercisable through 09/18/2035. Following the grant, Mr. Rongen beneficially owns 23,605 option shares directly. Of those options, 17,621 vested immediately on the grant date and 5,984 will vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of the grant date.
The Form 4 was filed as a single reporting person filing and bears a signature dated 09/22/2025 by an attorney-in-fact.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
